scholarly journals Serum Fluorescence of Advanced Glycation End Products: A Potential Screening Tool to Distinguish Between Diabetic Patients with and without Microvascular Complications

2020 ◽  
Author(s):  
Sadaf Ali ◽  
Nivedita L Rao
Keyword(s):  
Diabetes Mellitus ◽  
Screening Tool ◽  
Microvascular Complications ◽  
Diabetic Patients ◽  
Advanced Glycation ◽  
Type 2 Diabetic Patients ◽  
Glycation End Products ◽  
End Products ◽  
Type 2 Diabetic

Introduction: Enhanced formation and accumulation of Fluorescent Advanced Glycation End products (F-AGEs) in diabetes mellitus have been linked to increased risk of developing the associated vascular complications. Aim: To evaluate the potential of serum fluorescence levels of F-AGEs as screening tools to distinguish between type 2 diabetic patients with and without microvascular complications such as retinopathy, neuropathy. Materials and Methods: This cross-sectional study was conducted between June 2016 and June 2017, included 95 type 2 diabetic patients with more than 1 year of diabetes duration. Fasting blood glucose, glycated haemoglobin and total protein levels were estimated by automated methods. Serum F-AGEs were estimated by using a simple spectrofluorometric method. Microvascular complications due to diabetes mellitus were studied in each patient from medical records data on fundus examination for retinopathy and touch, vibration sensation detection for neuropathy. Diabetic patients were categorised into two groups as those without microvascular complications and those with microvascular complications-retinopathy and neuropathy. Statistical tests used for comparisons between groups were chi-square test for gender distribution, independent t-test for other parameters and Pearson’s correlations. The p-value <0.05 indicated significant difference between variables. Results: Mean age of the population was 55.1±5.3 years. Diabetic patients with microvascular complications (n=26) in the form of retinopathy, neuropathy had significantly higher levels of serum F-AGEs with mean 7.4±1.8 AU/g protein compared with diabetic patients without complications with mean value 1.5±0.7 AU/g protein (p<0.01). Conclusion: Two categories of serum fluorescent AGE values, without overlap, could be distinguished between diabetic patients with and without complications. Measurement of serum F-AGEs products has the potential to emerge as a simple, valuable screening tool to distinguish between diabetic patients with and without microvascular complications.

scholarly journals Advanced Glycation End Products and Antioxidant Status in Type 2 Diabetic Patients With and Without Peripheral Artery Disease

Diabetes Care ◽  
2007 ◽  
Vol 30 (3) ◽  
pp. 670-676 ◽  
Author(s):  
A. Lapolla ◽  
F. Piarulli ◽  
G. Sartore ◽  
A. Ceriello ◽  
E. Ragazzi ◽  
...  
Keyword(s):  
Antioxidant Status ◽  
Diabetic Patients ◽  
Advanced Glycation ◽  
Peripheral Artery ◽  
Type 2 Diabetic Patients ◽  
Glycation End Products ◽  
End Products ◽  
Artery Disease ◽  
Type 2 Diabetic

scholarly journals Increased Oxidation as an Additional Mechanism Underlying Reduced Clot Permeability and Impaired Fibrinolysis in Type 2 Diabetes

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Anna Lados-Krupa ◽  
Malgorzata Konieczynska ◽  
Artur Chmiel ◽  
Anetta Undas
Keyword(s):  
Oxidative Stress ◽  
Disease Duration ◽  
Fibrin Clot ◽  
Diabetic Patients ◽  
Advanced Glycation ◽  
Type 2 Diabetic Patients ◽  
Glycation End Products ◽  
End Products ◽  
Type 2 Diabetic

Aims. We sought to investigate whether enhanced oxidation contributes to unfavorable fibrin clot properties in patients with diabetes.Methods. We assessed plasma fibrin clot permeation (Ks, a measure of the pore size in fibrin networks) and clot lysis time induced by recombinant tissue plasminogen activator (CLT) in 163 consecutive type 2 diabetic patients (92 men and 71 women) aged 65 ± 8.8 years with a mean glycated hemoglobin (HbA1c) of 6.8%. We also measured oxidative stress markers, including nitrotyrosine, the soluble form of receptor for advanced glycation end products (sRAGE), 8-iso-prostaglandin F2α(8-iso-PGF2α), oxidized low-density lipoprotein (oxLDL), and advanced glycation end products (AGE).Results. There were inverse correlations betweenKsand nitrotyrosine, sRAGE, 8-iso-PGF2α, and oxLDL. CLT showed a positive correlation with oxLDL and nitrotyrosine but not with other oxidation markers. All these associations remained significant forKsafter adjustment for fibrinogen, disease duration, and HbA1c (allP<0.05), while oxLDL was the only independent predictor of CLT.Conclusions. Our study shows that enhanced oxidative stress adversely affects plasma fibrin clot properties in type 2 diabetic patients, regardless of disease duration and glycemia control.

scholarly journals Correlation of serum fluorescence of advanced glycation end products with diabetes duration and glycemic control in type 2 diabetic patients

2020 ◽  
Vol 7 (8) ◽  
pp. 3933-3938
Author(s):  
Sadaf Ali ◽  
Nivedita L. Rao
Keyword(s):  
Glycemic Control ◽  
Advanced Glycation End Products ◽  
Microvascular Complications ◽  
Diabetes Duration ◽  
Diabetic Patients ◽  
Advanced Glycation ◽  
Type 2 Diabetic Patients ◽  
Glycation End Products ◽  
End Products

Introduction: Advanced glycation end products (AGEs) and diabetes duration have roles in the development of the vascular complications associated with morbidity and mortality in diabetic patients. The present study was conducted to estimate and find the association between serum fluorescence levels of advanced glycation products with diabetes duration and glycemic control in type 2 diabetic patients. Methods: 46 patients who had diabetic duration of less than ten years and 49 patients with duration more than ten years were included in the study. Serum fluorescence of AGEs was measured using a simple spectrofluorometric method. Correlations of AGEs with diabetes duration, fasting glucose, and glycated hemoglobin levels were analyzed. The incidence of microvascular complications in patients of both groups was examined. Results: Significantly higher serum fluorescent AGE levels (p < 0.001) and higher incidence of microvascular complications (p = 0.000) were found in diabetic patients who had diabetes duration of more than ten years, poorer glycemic control and higher age. Serum levels of fluorescent AGEs showed significant positive correlations with duration of diabetes mellitus, glycated haemoglobin and fasting glucose levels. Conclusion: Screening patients for AGEs, intensive glycemic control, and therapeutic strategies that target molecular mechanisms involving advanced glycation end products are warranted in older patients with longer diabetes duration to minimize their risk of developing complications.

Sign in / Sign up

Export Citation Format

Share Document